San Diego – (business wire)–PhenoVista Biosciences (PhenoVista), a San Diego, Calif.-based contract research organization (CRO) and leading provider of both custom and off-the-shelf imaging-based assay services, today announced a strategic investment by Fujifilm Corporation. announced. Tokyo. Life Science Corporate Venture Capital (LS-CVC) Strategic Investment Fund of FUJIFILM Corporation has invested in a new high-content screening (HCS) assay service using FUJIFILM iCell® differentiation-induced pluripotent stem cells (iPSCs) and PhenoVista cleavage. We are investing in PhenoVista to accelerate development. edge imaging technology.
This investment builds on an existing strategic alliance between FUJIFILM Cellular Dynamics, Inc., a subsidiary of FUJIFILM Corporation (the world’s leading developer and manufacturer of human iPS cells) and PhenoVista. Through this partnership, which started in November 2021, FUJIFILM Cellular Dynamics will further expand its drug discovery business by jointly developing high-content imaging-based assays using highly biorelevant human iPSC-derived differentiated cells. Aim. These his HCS assay services using iPSCs are able to monitor the complex subcellular functions of individual human cells involved in disease progression, including cellular health, mitochondrial health and synaptogenesis. We support the drug discovery process of pharmaceutical companies.
“Fujifilm’s investment will accelerate PhenoVista’s exciting growth phase and further solidify our position as a leader in imaging-based analysis of complex cellular models.” PhenoVista’s current and future partners and collaborators will have early access to Fujifilm’s new cell models, a long-term trusted source of validated iPS cell models in the most relevant therapeutic areas Both our bespoke service platform and our Ready-2-Go service platform.”
Takatoshi Ishikawa, General Manager, Life Science Strategy Division, FUJIFILM Corporation, said: “Investment through the LS-CVC Fund will strengthen our partnership with PhenoVista and accelerate the development of iPSC-derived service areas, helping more patients get the new treatments they need, faster.”
“Fujifilm brings its extensive expertise in imaging to the life sciences sector and is collaborating with PhenoVista to help our mutual customers streamline the drug discovery process through the combination of highly relevant human cell types and strong HCS capabilities. Tomoyuki Hasegawa, President and CEO of FUJIFILM Cellular Dynamics, said: “iPSC.”
Launched in February 2022, LS-CVC is a newly established group within the Life Science Strategy Headquarters of Fujifilm in Tokyo. Fujifilm is initially investing 7 billion yen (approximately US$50 million) to launch a fund targeting cutting-edge biotechnology, primarily through partnerships with early-stage companies around the world. .
About PhenoVista Biosciences
PhenoVista Biosciences is a leading provider of disease-relevant cell-based assay services based in San Diego, CA. Comprised of PhD-level scientists with diverse expertise ranging from biomedical engineering to neurobiology, PhenoVista’s team works with clients to collaborate in a adaptable way to improve drug safety and We design and implement physiologically meaningful assays that predict efficacy. PhenoVista has earned a reputation for providing high quality data to biopharmaceutical clients through its unique and unparalleled combination of cutting-edge cell models and the latest quantitative imaging technology and data analysis capabilities. Their diverse repertoire includes the use of primary cells, iPSC-derived neurons and glia, and client engineering lines in various formats such as 2D, 3D, co-cultures and microfluidic systems. PhenoVista’s team provides clients worldwide with unmatched functional, structural, preclinical, and mechanistic data.
For more information, please visit phenovista.com.
